The European Medicines Agency accepted Pfizer's application to expand its label for blockbuster vaccine Prevenar 13 back in August, and so far, an advisory committee likes what it sees.
The cost of vaccinating a child in the world's poorest countries is much higher than it was in 2001--68 times higher, according to Medecins Sans Frontieres. The international charity has a problem with that, and it's asking pneumococcal disease vaccine makers Pfizer and GlaxoSmithKline to fix it.
Days after unveiling a $60 million deal with Genentech, personal genomics pioneer 23andMe struck a new database-driven collaboration with Pfizer. There is even talk of a possible resolution with the FDA in 2015.
Pfizer is well behind its rival titans in the race to cash in on a new class of cancer treatments. But instead of playing catch-up in skin cancer, the industry first immuno-oncology target, the drugmaker is skipping ahead to the next wave of malignancies.
Pfizer has written doctors in the U.K. warning them not to prescribe Lyrica knockoffs to treat neuropathic pain. Seems the company still has a live patent covering Lyrica's use against that type of nerve pain.
PCSK9 drugs are the next big market waiting to happen, and with rivals Sanofi/Regeneron and Amgen ahead in the development race, Pfizer wants to make sure it can lock down a solid share of the market. So beyond in-development anti-cholesterol antibody bococizumab, it's working on a wider PCSK9 "franchise," R&D chief Mikael Dolsten said Tuesday at the JP Morgan Healthcare Conference--and that includes a vaccine.
SAN FRANCISCO-- Keeping up the rear in a three-way race to commercialize the first of a new class of anticholesterol antibodies, Pfizer is at work on a pill that attacks the same target, planning to build a franchise in what is expected to be a blockbuster new therapeutic area.
The FDA issued an import alert on Monday, saying it was banning Eli Lilly's Cialis made at a plant in Australia because testing showed it contained not only the active pharmaceutical ingredient approved for Cialis but also the API that goes in Pfizer's competing erectile dysfunction drug Viagra. The problem, Lilly said in a statement, is that it doesn't currently have a plant in Australia, making Cialis or anything else.
23andMe's strategy of selling its database of genetic data to Big Pharma companies continues to bear fruit. The Google-backed company is sharing data about the DNA of 650,000 individuals with Pfizer to help that company in its R&D efforts.
If you've watched television lately, you know that Pfizer and Bristol-Myers have been spending a lot of money on advertising to back their new anticoagulant, Eliquis. So have rival Boehringer Ingelheim, with its Pradaxa drug, and Bayer and Johnson & Johnson with Xarelto.